PubMed Journals Articles About "Conatus Raises Hepatitis Studies" RSS

23:25 EST 22nd February 2019 | BioPortfolio

Conatus Raises Hepatitis Studies PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Conatus Raises Hepatitis Studies articles that have been published worldwide.

More Information about "Conatus Raises Hepatitis Studies" on BioPortfolio

We have published hundreds of Conatus Raises Hepatitis Studies news stories on BioPortfolio along with dozens of Conatus Raises Hepatitis Studies Clinical Trials and PubMed Articles about Conatus Raises Hepatitis Studies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Conatus Raises Hepatitis Studies Companies in our database. You can also find out about relevant Conatus Raises Hepatitis Studies Drugs and Medications on this site too.

Showing "Conatus Raises Hepatitis Studies" PubMed Articles 1–25 of 25,000+

Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana.

Viral hepatitis continues to play significant role in causing morbidity and mortality in sub-Saharan Africa. Apart from the few population based studies available, not many have investigated the burden of these viruses in jaundiced patients. Among the few studies, hepatitis E is the least studied among jaundiced patients. This study was aimed at describing the frequency, distribution and risk of the different hepatitis viruses among jaundiced patients reporting to the second largest teaching hospital in Gha...

Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care.

Hepatitis C has increasingly affected women of child-bearing age over the past few years as a result of the opioid epidemic. In this review, we discuss the effect of hepatitis C on pregnancy outcomes, effect of pregnancy on hepatitis C, as well as implications on management of hepatitis C during pregnancy.

Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.

Direct-acting antiviral agents have revolutionised hepatitis C treatment. In 2014, the Swiss Hepatitis Strategy was developed to eliminate hepatitis C virus (HCV) infection and the associated liver-related morbidity and mortality by 2030. Though numerous national studies and assessments have identified a relatively low prevalence rate of 0.7% in the country, little has been done to identify the epidemiology of HCV on the regional, or micro, level. This study aimed to identify scenarios to achieve the object...

Pretreatment Hepatitis B Viral Load Predicts Long-term Hepatitis B Response after Anti-hepatitis C Therapy in Hepatitis B/C Dual-infected Patients.

We aimed to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C (HCV) dual-infected patients after anti-HCV therapy.

miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.

Many studies have shown that some microRNAs (miRNAs) play an important role in the pathogenesis of chronic hepatitis B (CHB) infection. In this study, we aimed to explore the role and molecular mechanism of miRNA-548ah in the replication and expression of the hepatitis B virus (HBV).

Hepatitis E Virus Genotype 1 and Hepatitis A Virus Dual Infection in Pediatric Patients with a Low Socioeconomic Status from Mexico.

We aimed to detect and characterize hepatitis E virus (HEV) RNA in sera samples from a pediatric population infected with the hepatitis A virus (HAV) exhibiting acute hepatitis and to correlate the infection status with the clinical outcome.

Comparison of ARIMA and GM(1,1) models for prediction of hepatitis B in China.

Hepatitis B virus (HBV) infection is a major public health threat in China for China has a hepatitis B prevalence of more than one million people in 2017 year. Disease incidence prediction may help hepatitis B prevention and control. This study intends to build and compare 2 forecasting models for hepatitis B incidence in China.

World Hepatitis Day - July 28, 2018.

World Hepatitis Day is commemorated each year on July 28 with the goal of promoting awareness and inspiring action to prevent and treat viral hepatitis. The World Health Organization's (WHO's) theme of this year's World Hepatitis Day is "Test. Treat. Hepatitis" to underscore the urgent need to scale up testing and treatment activities.

Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda.

Chronic hepatitis B infection affects 240 million people, with the highest prevalence in Africa and Asia, and results in 700 000 deaths annually. Access to diagnostics, particularly for hepatitis B virus viral load quantification (HBV DNA), is a major barrier to treatment. We aimed to test World Health Organization guidelines for hepatitis B management in resource-limited settings.

Validity of hepatitis B and hepatitis C case definitions.

Globally, an estimated 257 million people are living with chronic hepatitis B (HBV) infection and an estimated 71 million people with the chronic hepatitis C virus (HCV). The true public health dimensions and impact of hepatitis epidemics are poorly understood. Case definitions are fundamental parts of disease surveillance, representing sets of standardised criteria used to assess whether or not a person has a certain disease. The study evaluated the sensitivity and specificity of hepatitis B and hepatitis ...

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Hepatitis delta virus (HDV) infection is the most rapidly progressive chronic viral hepatitis. Little is understood about the immune responses to HDV.

Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016.

The epidemiology of acute hepatitis A and E has been changing over the last 2 decades. The impact of concomitant chronic hepatitis B (CHB) on clinical outcomes remains unclear. We aimed to evaluate the morbidity and mortality of patients with acute hepatitis A or E with and without underlying CHB.

Cross sectional study of chronic hepatitis B prevalence among healthcare workers in an urban setting, Sierra Leone.

Hepatitis B is a serious public health problem across sub-Saharan Africa. Sierra Leone has no national hepatitis B strategy plan or high quality estimates of prevalence. Healthcare workers are perceived as an at-risk group for hepatitis B. We assessed the prevalence of hepatitis B among healthcare workers at two hospital sites in Freetown, Sierra Leone.

Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS).

According to death certificates, approximately 1800 persons die from hepatitis B annually in the United States (US); however, this figure may underestimate the true mortality from chronic hepatitis B (CHB).

A territory-wide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong.

Viral hepatitis epidemiological data is important for the WHO plan of eliminating viral hepatitis. We aimed to document the prevalence of viral hepatitis A to E in Hong Kong.

Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection?

In the United States, blood donor testing for hepatitis B surface antigen (HBsAg) was initiated in the early 1970s. More recently, testing for antibody to hepatitis B core antigen (anti-HBc) and hepatitis B virus (HBV) DNA have been added. The incidence of hepatitis B has been declining. This study reviews the current status of testing and questions the need for continuation of HBsAg testing.

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R).

 More than 250 000 patients suffer from chronic hepatitis C in Germany. Several potent, direct-acting antiviral drugs have been approved since 2014. The aim of the German Hepatitis C-Registry (DHC-R) is to describe the epidemiology and patient care of hepatitis C and to investigate the efficacy and safety of new treatment options in real-world settings.

The Hepatitis C Awareness Through to Treatment (HepCATT) study: Improving the cascade of care for hepatitis C virus-infected people who inject drugs in England.

Previous studies have shown low rates of diagnosis and treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID). Our aims were to test the effect of a complex intervention ("HepCATT") in drug and alcohol clinics - primarily, on engagement of HCV-positive PWID with therapy, and, secondarily, on testing for HCV, referral to hepatology services, and start of HCV treatment.

Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B.

We compared the vaccine effectiveness of monovalent and combination hepatitis B vaccine regimens in infants born to chronic hepatitis B carrier mothers.

In drug-induced, immune-mediated hepatitis, interleukin-33 reduces hepatitis and improves survival independently and as a consequence of FoxP3+ T-cell activity.

Immune-mediated, drug-induced hepatitis is a rare complication of halogenated volatile anesthetic administration. IL-4-regulated Th2-polarized reactions initiate this type and other types of hepatitis, while the mechanisms that regulate the severity remain elusive. IL-33 is an innate, IL-4-inducing, Th2-polarizing cytokine that has been detected in patients with liver failure and has been associated with upregulated ST2+Foxp3+CD4+CD25+ T cells; however, roles for IL-33 in drug-induced hepatitis are unclear....

Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients.

We aimed to identify HBc amino acid differences between subgroups of chronic hepatitis B (CHB) patients.

Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis.

Hepatocellular carcinoma (HCC) is one of the most common cancers and the second leading cause of cancer-related deaths in men worldwide. Surgical resection of HCC remains the mainstay treatment procedure. As a result of hepatitis viral infection, the postoperative survival outcome in patients with HCC is not satisfactory. Recently, studies have reported that due to its treatment effect on hepatitis infection, pegylated interferon (Peg-IFN)-based therapy could improve the survival outcome after the treatment...

New treatment option for delta virus: is a cure in sight?

Current treatment of chronic hepatitis D viral infection with interferons is poorly tolerated and effective only in a minority of patients. Despite Delta virus causing the most severe form of chronic viral hepatitis no other treatments are available. After many years of inactivity there is now hope for new treatment approaches for Delta virus and some are likely to enter clinical practice in the near future. Four new treatment approaches are currently being evaluated in phase 2 studies. These involve the he...

Analytical Performance of Newly Developed Rapid Point-of-Care Test for the Simultaneous Detection of Hepatitis A, B, and C Viruses in Serum Samples.

Although immunoassays play a major role in the detection of hepatitis viruses, there is a need for a point-of-care (POC) test. We evaluated the EuDx™-HE (A,B,C) kit (EUDIPIA, Cheongju, Korea), which detects anti-hepatitis A virus (HAV) immunoglobulin M (IgM), hepatitis B virus surface antigen (HBsAg), and anti-hepatitis C virus (HCV) immunoglobulin G (IgG) simultaneously using an immunochromatographic method within 15 min.

Vertical hepatitis C transmission - authors' experiences.

Vertical hepatitis C virus (HCV) transmission and persistence of anti-HCV antibodies were retrospectively investigated since 1999 in a group of 244 children whose mothers had a history of hepatitis C.

Quick Search